Published: April 20, 2020

Introduction {#sec1}
============

HIV-1 broadly neutralizing antibodies (bNAbs), when passively administered, demonstrated viral suppression in patients ([@bib8], [@bib9], [@bib45]) and protection in simian/human immunodeficiency virus (SHIV) macaque challenge models ([@bib55]). To date, the isolated HIV-1 bNAbs fall into seven categories defining seven major conserved sites of vulnerability on the HIV-1 envelope (Env)---namely the first and second variable (V1V2) apex ([@bib52], [@bib77]), V3 glycan supersite ([@bib56], [@bib78]), CD4-binding site (CD4bs) ([@bib62], [@bib84], [@bib91]), silent face ([@bib65], [@bib93]), subunit interface ([@bib19], [@bib28]), fusion peptide ([@bib34]), and membrane proximal external region (MPER) ([@bib27], [@bib81]). The majority of these bNAbs have been discovered by using soluble probes produced with Envglycoprotein (gp120) monomers or gp140 stabilized trimers. Because the HIV-1 Env adopts multiple trimeric conformations ([@bib44], [@bib46]), current soluble Env probes might not fully present them, and the identification of HIV-1 bNAbs remains challenging.

All of the HIV-1 bNAbs isolated to date are immunoglobulin G (IgG), the dominant antibody class in peripheral blood. However, HIV-1 spreads mainly through mucosal exposures. Dominant in mucosal secretions, IgA has long been the class of bNAbs desired at the portal of entrance to block infection ([@bib36]). Unlike IgG, for which the class-switching from the IgM naive B cell receptor (BCR) occurs in the germinal centers of lymph nodes, the IgA response is predominantly elicited in the Peyer's patches of gut mucosa that favors the IgM naive BCR class-switching to IgA ([@bib47]). The IgA response to HIV-1 might be impaired by the accelerated loss of CD4^+^ T cells at gut mucosa ([@bib64]); nonetheless, HIV-1-specific IgA has been documented and has a role that has been controversial ([@bib43], [@bib90]). On one hand, serum and mucosal IgA from infected individuals has been shown to inhibit HIV-1 ([@bib6], [@bib83]), although monoclonal IgA with neutralizing ability has not been isolated. On the other hand, serum IgA from some HIV-1-infected individuals has been reported to exhibit antibody-dependent enhancement of viral infection ([@bib35]), and the plasma IgA response to HIV-1 Env has been associated with increased risk of HIV-1 acquisition in the RV144 vaccine trial ([@bib25]). To address the question of whether or not IgA bNAbs are produced during HIV-1 infection and to identify additional bNAbs, we used vesicular stomatitis virus (VSV) to display functional membrane-embedded HIV-1 Env trimers ([@bib41]) on the surface of viral particles. This approach enabled us to probe Env-specific B cells, isolate monoclonal bNAbs from HIV-1 infected individuals, and annotate the bNAb lineage members, including IgA, from the donor BCR repertoires.

Results {#sec2}
=======

VSV-Based Env Probes Identified HIV-1 bNAbs {#sec2.1}
-------------------------------------------

Compared with HIV-1 virions or virus-like particles ([@bib7]), the VSV particles presented two advantages: first, VSV particles display more Env spikes on the surface---the number of Env spikes on HIV-1 is estimated to be about a dozen ([@bib32], [@bib94], [@bib95]), whereas the number on VSV is in the hundreds ([@bib73]), thus increasing the avidity for B cell binding; and second, in the case of viral membrane rupture, the exposure of VSV matrix and capsid does not lead to cross-reactivity with memory B cells targeting the HIV-1 Gag that is irrelevant to virus neutralization. Using a molecular clone of VSV (Indiana strain), we replaced the extracellular and transmembrane domains of VSV-G with the AD17 HIV-1 Env, a clade B transmitted founder (T/F) strain ([@bib39]) but retained the intracellular portion of VSV-G to facilitate Env incorporation ([Figure 1](#fig1){ref-type="fig"}A). The recombinant VSV~AD17~ was rescued by transfection in 293T cells, expanded in GHOST.R5 cells, and labeled with phycoerythrin (PE). The labeled VSV~AD17~-PE particles stained 3.55% of 293T cells expressing VRC07 ([@bib60]) on the surface, compared with 0.8% of unmodified 293T cells ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We applied this probe to a clade B chronically infected subject, M4008, whose plasma neutralized all of the 10 HIV-1 Env strains tested, with a 50% inhibitory dilution (ID~50~) against AD17 at about 1:400 ([Figure S1](#mmc1){ref-type="supplementary-material"}B). From 4 million M4008 peripheral blood mononuclear cells (PBMCs), we pre-sorted 0.16 million CD3^−^CD19^+^ B cells, then stained them with VSV~AD17~-PE and isolated 87 IgG^+^PE^+^ B cells that constituted ∼1.5% of total IgG^+^ B cells ([Figure 1](#fig1){ref-type="fig"}B). Using single-B-cell RT-PCR, we recovered two bNAbs, M4008_N1 and M4008_N2 ([Figure S1](#mmc1){ref-type="supplementary-material"}C), as well as six tier-1-neutralizing or non-neutralizing monoclonal antibodies (mAbs) ([Table 1](#tbl1){ref-type="table"}).Figure 1VSV~AD17~ as B Cell Probe for HIV-1 bNAb Isolation(A) Schematic VSV~AD17~ constructs. Abbreviations are as follows: mNG, monomeric NeonGreen; TM, transmembrane; CT, cytoplasmic tail.(B) Fluorescence-activated cell sorting (FACS) of pre-sorted B cells from donor M4008 for single IgG^+^ memory B cells bound to VSV~AD17~-PE. Abbreviations are as follows: SSC-A, side-scatter area; FSC-A, forward-scatter area.(C) FACS of pre-sorted B cells from donor M1214 for single IgM^−^CD27^+^ memory B cells bound to VSV~AD17~-mNG.(D) Neutralization breadth and potency of three bNAb clones from M4008 and M1214 evaluated on a total of 120 cross-clade HIV-1 Env strains. The dendrograms show the Env protein sequence distance, with clades, including circulating recombinant forms (CRFs), indicated. The neutralization potency is color-coded for the branch of each Env tested. The data under the dendrograms show the number and percent of viruses neutralized with an IC~50~ \< 50 μg/mL and the geometric mean IC~50~ value for viruses neutralized with an IC~50~ \< 50 μg/mL.Table 1Summary of the Isolated HIV-1 bNAbs and Env-Specific mAbs for Isotype, Genetic Composition, Epitope, and Neutralization CharacteristicsmAb IDDonorIsotypeV-gene^∗^(hypermutation)CDR3 length(amino acid)EpitopeNeutralizationM4008_N1M4008IgG2 (IgA)VH1-69 (28%) VK1-5 (24%)H3: 17, L3: 9V3 looptier-2 (B), 38% breadthM4008_N2M4008IgG3VH4-61 (28%) VL3-21 (11%)H3: 15, L3: 11Env trimer or gp41tier-2, weak potencyM4008_b3M4008IgG1VH3-30 (14%) VL1-47 (15%)H3: 20, L3: 11gp120, CD4bs^∗^tier-1M4008_b3.2M4008IgG1VH3-30 (19%) VL1-47 (12%)H3: 20, L3: 11gp120, CD4bstier-1M4008_b4M4008IgG1VH1-18 (16%) VK3-20 (12%)H3: 21, L3: 9gp120, CD4bstier-1M4008_b5M4008IgG1VH4-34 (13%) VK4-1 (3%)H3: 23, L3: 10gp120, V3 tiptier-1M4008_b6M4008IgG1VH1-69-2 (15%) VK1-39 (12%)H3: 14, L3: 9gp120, V3 tiptier-1M4008_b7M4008IgG3VH3-30 (15%) VK2-28 (15%)H3: 17, L3: 10gp41NoneM1214_N1M1214IgG1 (IgA)VH3-66 (35%) VL2-11 (24%)H3: 18, L3: 11V2V5 corridortier-2, 57% breadthM1214_N2M1214IgG1VH4-34 (30%) VK2-24 (17%)H3: 11, L3: 9V3 glycanstier-2 (B), 26% breadthM1214_N2.2M1214IgG1VH4-34 (27%) VK2-24 (20%)H3: 11, L3: 9V3 glycanstier-2 (B), 20% breadthM1214_N3M1214IgG1VH6-1 (24%) VL1-44 (20%)H3: 19, L3: 11V3 glycanstier-2, partial neutralizationM1214_b4M1214IgG1VH1-69 (26%) VK3-20 (20%)H3: 15, L3: 8gp41None[^3]

To improve the sensitivity and specificity of the VSV~AD17~ probe, we next used a VSV backbone encoding monomeric NeonGreen (mNG)---a bright green fluorescent protein variant, fused to the VSV-P gene ([@bib33], [@bib71]) ([Figure 1](#fig1){ref-type="fig"}A). We also propagated the virus in GHOST.R5 cells transfected with VSV-G, followed by a single round of replication through 293T-furin cells that overexpressed human furin to improve HIV-1 Env cleavage ([Figure S1](#mmc1){ref-type="supplementary-material"}D). The resulting VSV~AD17~-mNG stained ∼0.3% of unmodified 293T, whereas it gave a 2- to 3-fold higher signal (0.8%) on 293T cells expressing surface PGT145 ([@bib78]) ([Figure S1](#mmc1){ref-type="supplementary-material"}D). We applied VSV~AD17~-mNG to another clade B chronically infected subject, M1214, whose plasma neutralized 9 out of 10 HIV-1 Env strains tested, with an ID~50~ against AD17 at about 1:250 dilution ([Figure S1](#mmc1){ref-type="supplementary-material"}B). From 50 million M1214 PBMCs, we pre-sorted 0.5 million CD3^−^CD19^+^ B cells, then stained with VSV~AD17~-mNG and sorted 51 mNG^+^ B cells that constituted ∼0.1% of IgM^−^CD27^+^ memory B cells ([Figure 1](#fig1){ref-type="fig"}C). Using single-B-cell RT-PCR, we recovered four bNAbs, M1214_N1, M1214_N2, a clonal variant M1214_N2.2, and M1214_N3 ([Figure S1](#mmc1){ref-type="supplementary-material"}E), and one non-neutralizing mAb, M1214_b4 ([Table 1](#tbl1){ref-type="table"}).

Of the five unique bNAbs isolated, we tested three (M4008_N1, M1214_N1, and M1214_N2), along with their distant clonal variants, for neutralization of an extended multi-clade panel of 120 Env isolates ([Figure 1](#fig1){ref-type="fig"}D and [Table S1](#mmc1){ref-type="supplementary-material"}). The other two bNAbs, M4008_N2 and M1214_N3, were not tested in the extended panel because of weak and partial neutralization, respectively ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1E). The M1214_N1 clone exhibited the best breadth (65%) and potency (0.19 μg/mL geometric mean 50% inhibitory concentration \[IC~50~\]) against the 120 Env panel, followed by the M4008_N1 clone with 42% breadth and 0.77 μg/mL potency and the M1214_N2 clone with 31% breadth and 0.16 μg/mL potency. Both M4008_N1 and M1214_N2 exhibited a clade B preference, neutralizing 17 out of 25 (68%) clade B Envs tested. Interestingly, M4008_N2, M1214_N2, M1214_N2.2, and M1214_N3 neutralized the difficult-to-neutralize clade B strain BL01, which is resistant to all previously described gp120-directed bNAbs ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1E). Of the 10 HIV-1 Env strains neutralized by donor M4008 plasma ([Figure S1](#mmc1){ref-type="supplementary-material"}B), the isolated bNAbs M4008_N1 and M4008_N2 neutralized 9, the exception being Du156.12 ([Figure S1](#mmc1){ref-type="supplementary-material"}C and [Table S1](#mmc1){ref-type="supplementary-material"}). Similarly, of the 9 HIV-1 Env strains sensitive to donor M1214 plasma ([Figure S1](#mmc1){ref-type="supplementary-material"}B), M1214_N1 and M1214_N2 neutralized 8, again the exception being Du156.12 ([Table S1](#mmc1){ref-type="supplementary-material"}). Overall, the VSV~AD17~ probe efficiently identified multiple bNAb clones from each donor, and the isolated bNAb clones accounted for the majority of the donor plasma neutralizing activity.

Identification of bNAb Lineages That Class-Switched to Both IgG and IgA {#sec2.2}
-----------------------------------------------------------------------

From the donor PBMCs, we also amplified and sequenced the expressed BCR messenger RNA (mRNA) spanning the variable region of μ, γ, α, κ, and λ chains by using 5′ rapid amplification of cDNA ends (RACE) PCR and performed Illumina sequencing ([@bib79]). Using the isolated bNAbs as references, we produced divergence-identity plots to identify additional members of the bNAb lineages ([Figure 2](#fig2){ref-type="fig"}A). For M4008_N1 and M1214_N1, the BCR repertoire identified clonally related γ and corresponding light-chain transcripts, but not μ transcripts, as expected. Surprisingly, the BCR repertoire also identified clonally related α transcripts, indicating that these bNAb lineages class-switched to both IgG and IgA, a phenomenon unknown for HIV-1 bNAbs before. Further phylogenetic analyses of clonal members of M4008_N1 and M1214_N1 supported both direct (primary) and indirect (secondary) class-switch mechanisms generating the observed IgA transcripts ([Figure 2](#fig2){ref-type="fig"}B). For M4008_N1.3 IgA and M1214_N1.2 IgA branches, there were closely related IgG reads consistent with a secondary class-switch from IgG to IgA. Governed by the deletional process of class-switch recombination (CSR) that splices out the constant genes between the antibody variable region and the selected downstream constant gene ([@bib12]), switching from IgG to IgA is theoretically plausible given the genomic locations of human immunoglobulin heavy-chain constant genes ([Figure 2](#fig2){ref-type="fig"}C). Because the PCR primers used for the donor BCR next-generation sequencing (NGS) did not distinguish among IgG and IgA subclasses, we could only infer that, for the probe-identified M4008_N1 IgG2 lineage, its secondary class-switching from variant N1.3 IgG to N1.3 IgA would be IgA2, and for the probe-identified M1214_N1 IgG1 lineage, its secondary class-switching from variant N1.2 IgG to N1.2 IgA could be IgA1 or IgA2 ([Figure 2](#fig2){ref-type="fig"}C). Although supported by data from B cell cultures ([@bib88]) and BCR sequencing ([@bib26], [@bib42]), here the IgG to IgA switching mechanism was evident in human antibodies with known specificity and function. For the M4008_N1.4 IgA branch, however, no IgG transcript was closely clustered with IgA transcripts that would support an IgG ancestor. Thus, a primary class-switch mechanism from a common IgM ancestor (M4008_N1) to both IgG and IgA appeared more likely. Because the BCR repertoire data did not contain the IgA subclass information, the M4008_N1.4 IgA cluster could be IgA1 or IgA2 ([Figure 2](#fig2){ref-type="fig"}C). To assess the function of NGS-identified IgG and IgA lineage members, we synthesized the representative heavy- and light-chain sequences of each clonal cluster ([Figure 3](#fig3){ref-type="fig"}A) and expressed the clonal variants as monomeric IgG1, IgA1, or IgA2 or dimeric IgA2 (dIgA2). The clonal variants of M4008_N1 and M1214_N1 demonstrated various degrees of neutralizing activity ([Figure 3](#fig3){ref-type="fig"}B), and some were comparable to that of the prototype bNAbs M4008_N1 and M1214_N1 ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1E). To assess the physiological relevance of the IgA bNAb members and help rule out possible sequencing or PCR artifacts, we purified the IgA fraction from M1214 plasma and found that the M1214 plasma IgA indeed neutralized the same four HIV-1 Env strains as did the M1214_N1.2 IgA1 bNAb ([Figure 3](#fig3){ref-type="fig"}B). Thus, IgA bNAbs were produced during HIV-1 infection and contributed to the overall plasma neutralizing activity. For donor M4008, however, there was insufficient plasma available to test purified IgA neutralization activity. We note that only a subset of bNAbs class-switched to both IgG and IgA. For example, all members of the M1214_N2 bNAb lineage contained only IgG but no IgA or IgM transcripts ([Figure 2](#fig2){ref-type="fig"}A). We speculate that in these donors, a local environment favoring IgA class-switch ([@bib10]) might have promoted and selected certain bNAb clones, either as activated IgM or clonally expanded IgG, to further switch to IgA. The lack of IgM detection might have resulted from the relative rarity of circulating gut-derived IgM^+^ memory B cells and plasma cells, although in principle, mucosal pentameric IgM could protect against HIV-1 ([@bib21]). Indeed, mucosal surfaces are likely a more appropriate place for the detection of IgM bNAbs ([@bib48]), particularly in infected individuals with a concomitant primary or secondary IgA deficiency.Figure 2Identification of bNAb IgG and IgA Lineage Members by NGS of BCR Repertoires(A) Subsets of expressed heavy-chain (μ, γ, and α) and light-chain (κ and λ) sequences are plotted as sequence identity (y axis) to each bNAb reference, as indicated, and sequence divergence (x axis) from the putative germline V-genes. The isolated bNAbs and clonal variants are marked with red and magenta Xs, respectively.(B) Phylogenetic tree of bNAb lineage members identified by the donor BCR repertoires. Indicated are the representative sequences of each major cluster that have been synthesized and tested for neutralization function.(C) Schematic illustrations of the order of human Ig heavy-chain constant genes and interpreted class-switching events of the two bNAb lineages, M4008_N1 and M1214_N1 (as indicated), with clonally related IgG and IgA members.Figure 3Sequence Alignment and Neutralization Assessment of Representative bNAb Lineage Members(A) The deduced aa sequences of the variable region of bNAbs and representative lineage members are shown. Framework (FR) and complementarity-determining regions (CDRs) are indicated above the sequence alignment. The top sequence in each group represents the deduced germline V-gene sequence. The dot symbol marks deletion; red residues indicate somatic hypermutations, and magenta residues indicate common somatic hypermutations among lineage members, as shown.(B) The bNAb lineage members were reconstituted as IgG1, IgA1, IgA2, or dIgA2, and then assessed for neutralization against the indicated Env pseudoviruses. The number and percent of aa difference from the probe-identified bNAb reference is indicated in parenthesis for the heavy-chain variable region of each clonal member. The M4008_N1 clonal members shown were paired with N1_K2 κ chain, and the M1214_N1.2 clonal members shown were paired with N1.2 λ chain. Also shown is the neutralization profile of the purified IgA fraction (polyclonal) from donor M1214 plasma. The VSV~AD17~ probe strain AD17 is highlighted in blue. Neutralization was performed in duplicate wells, and the data shown are means with SEM.

Site of Vulnerability Mapped to gp120 V3 Loop {#sec2.3}
---------------------------------------------

We next mapped the epitopes of the isolated bNAbs, first by comparing neutralization sensitivities of the HIV-1 strain JR-FL between the wild-type (WT) and mutant that lacked a glycan at N160, N301, or N332. Compared with that of WT JR-FL, the neutralization sensitivities of the mutant viruses were either comparable or enhanced for M4008_N1, M4008_N2, and M1214_N1; however, the mutations removing a glycan at N301 or N332 substantially reduced or abolished M1214_N2 and M1214_N3 neutralizing activity, indicating that the V3 stem glycans at N301 and/or N332 were a target for these bNAbs ([Figure 4](#fig4){ref-type="fig"}A). Competition ELISA showed that known V3-directed mAbs such as PGT128, 447-52D, 2219, and 2424 each effectively competed with M4008_N1-biotin binding to JR-FL gp120 ([Figure 4](#fig4){ref-type="fig"}B), suggesting that the epitope of M4008_N1 involved the V3 loop; meanwhile, CD4-Ig but not CD4bs-directed bNAbs also blocked M4008_N1-biotin binding. Unlike PGT128, which relies on the V3 stem glycans at N301 and N332 for gp120 binding ([@bib56]), M4008_N1 was glycan-independent given that it bound equally well to JR-FL gp120 treated or not treated with endoglycosidase H (Endo H). Altogether, the M4008_N1 mapping data suggested a previously undefined bNAb epitope that is V3-directed, glycan-independent, and incompatible with the CD4-triggered conformation of V3. Competition ELISA performed on CH505 SOSIP indicated a different epitope for bNAb M1214_N1, which was effectively competed by both CD4-Ig and CD4bs-directed bNAbs such as VRC01, VRC-PG04, N6, and N49P7 ([Figure 4](#fig4){ref-type="fig"}B). These data indicated that the M1214_N1 epitope overlapped with the CD4bs, and that the CD4-triggered changes in SOSIP conformation ([@bib80]) disrupted the M1214_N1 epitope, because after CD4-Ig bound to CH505 SOSIP, the binding of M1214_N1-biotin was poor.Figure 4Epitope Mapping of HIV-1 bNAbs(A) Epitope mapping of bNAbs by comparison of neutralization profiles of each bNAb on the HIV-1 strain JR-FL, as WT, treated with Kifunensine (Kif), or with indicated point mutations. Neutralization was performed in duplicate wells, and the data shown are means with SEM.(B) Epitope mapping of bNAbs by standard and competition ELISAs. The competition ELISAs were performed with a single concentration of biotinylated reagent (bNAbs or CD4-Ig, as indicated) binding to JR-FL gp120 or CH505 SOSIP. The unlabeled competing mAbs or CD4-Ig were titrated into the ELISAs at increasing concentrations to evaluate the effect on biotinylated reagent binding.

Structural Definition of the bNAb M1214_N1 Epitope {#sec2.4}
--------------------------------------------------

We further determined the epitope of M1214_N1 by deriving a 4.86-Å-resolution cryogenic electron microscopy (cryo-EM) structure of the antigen-binding fragment (Fab) of M1214_N1 in complex with the CH505 SOSIP trimer ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S2](#mmc1){ref-type="supplementary-material"}). The structure revealed an elongated epitope of M1214_N1, extending from V2 to V5 and centered on the ridge of the CD4-binding loop ([@bib37], [@bib87]), thus named "V2V5 corridor" epitope ([Figure 5](#fig5){ref-type="fig"}C). The M1214_N1 epitope partially overlapped with the CD4bs at the CD4-binding loop and V5, consistent with its ability to compete with CD4-Ig and CD4bs-directed bNAbs to bind to CH505 SOSIP ([Figure 4](#fig4){ref-type="fig"}B). However, M1214_N1 approached the CD4-binding loop from the opposite (the other) side of that contacted by CD4 and CD4bs-directed bNAbs. M1214_N1 interacted with gp120 primarily through its heavy chain, which contributed almost 80% of the buried surface area of the antibody Fab. A long 18 amino acid (aa) CDR H3 loop (by Kabat definition) reached to a valley below the V1V2 β barrel ([@bib22], [@bib54]), contacting a short turn (the integrin binding site kink) ([@bib54]) between the V1V2 C and C' strands ([Figures 5](#fig5){ref-type="fig"}D and 5E). The heavy chain of M1214_N1 also contacted V5 via CDR H2. The light chain of M1214_N1 contributed minor interactions with gp120, contacting residue Q183 on the C' strand of V1V2 and the glycans at N197 and N386. Interestingly, the light chain of M1214_N1 was located on the Env apex side, opposite to that of the known CD4bs bNAbs. Overall, the M1214_N1 epitope was distinct from the CD4bs by reaching to a long corridor region between glycans at N197 and N386, and contacting V2 at the Env apex side, away from the CD4bs. The contacts of M1214_N1 with the N197 glycan could restrict the movement of the V3 loop from the neighboring protomer ([Figure 5](#fig5){ref-type="fig"}F). Together with its contacts on the V1V2 β barrel, the binding of M1214_N1 stabilized the "closed" conformation of the prefusion Env trimer, as evidenced by reduced binding of mAbs that preferentially recognize the "open" Env conformation, such as anti-V3 crown mAbs 447-52D ([@bib23]) and AD358_b7 ([@bib29]), as well as mAb 17b ([@bib37]) that recognizes the co-receptor-binding site (CoRbs). As expected, the bNAb VRC01 Fab also stabilized the SOSIP "closed" conformation to a similar degree, whereas the 2-domain soluble CD4 (sCD4) induced the "open" Env conformation that markedly enhanced the binding by 17b but no or minimum enhancement of binding by the anti-V3 crown mAbs ([Figure S3](#mmc1){ref-type="supplementary-material"}). An analysis of HIV-1 Env sequence from over 5,000 circulating strains indicated that the M1214_N1 contact residues on gp120 are well conserved (mean entropy score of 0.8) ([Table S2](#mmc1){ref-type="supplementary-material"}), comparable to the conservation scores of the epitopes targeted by CD4bs and fusion peptide bNAbs ([@bib14]). The conservation of this epitope explained the \> 60% neutralization breadth for the M1214_N1 clone. However, the V2 contacts (entropy scores of 0.365--0.806) to M1214_N1 that were less conserved than those in the CD4bs including the CD4-binding loop (entropy scores of 0.787--0.992, excluding L369; [Table S2](#mmc1){ref-type="supplementary-material"}) likely accounted for the lower neutralization breadth (65%) of M1214_N1 compared with that of the best CD4bs bNAbs (\> 90%) such as the VRC01 class (note that L369 is not a contact residue for VRC01) ([@bib91]).Figure 5Cryo-EM Structure of M1214_N1 Fab in Complex with CH505 SOSIP Trimer(A) Structural model of a CH505 gp120/gp41 protomer. The variable (V1-V5) regions and CD4-binding loop in gp120 and HR1 and HR2 helices in gp41 are highlighted, with the same color scheme throughout the figure.(B) Cryo-EM structure of three M1214_N1 Fabs (ribbon) on a CH505 SOSIP trimer in side (left) and top (right) views. Glycans on the trimer are depicted in black sticks. For clarity, only the Fv domains of M1214_N1 are shown.(C) Comparison of the binding site of M1214_N1 (hot pink) to that of CD4 (orange) (Protein Data Bank \[PDB\]: 5U1F) and the CD4bs-directed bNAb VRC-PG04 (purple) (PDB: [3J5M](pdb:3J5M){#intref0135}). The dashed line depicts the CD4-binding loop ridge.(D) Env residues with surface contact areas \> 10 Å^2^ in M1214_N1 binding are shown in sticks.(E) Close-up view of the pocket accommodating CDR H3 of M1214_N1.(F) Position change of the N197 glycan on M1214_N1-bound CH505 SOSIP compared with a ligand-free BG505 SOSIP (PDB: [4ZMJ](pdb:4ZMJ){#intref0140}), restricting the movement of the V3 loop from the neighboring protomer (V3′).

Discussion {#sec3}
==========

The VSV~AD17~ probes employed here identified five HIV-1 bNAbs, providing a proof-of-concept that the VSV particles with functional membrane-embedded HIV-1 Env trimers are effective at probing B cells for bNAb isolation. Given the advantageous properties of the VSV~ENV~ particles that are portable, can be conveniently propagated to high titers, and have the flexibility to swiftly insert various HIV-1 Envs including T/F Envs, it becomes feasible to isolate bNAbs from a large number (i.e., dozens) of donor samples. The probe-identified bNAbs were then used as references to identify other bNAb lineage members from the NGS data of donor BCR repertoires. The repertoire analysis identified two bNAb lineages, M4008_N1 and M1214_N1, that were highly unusual in that they class-switched to both IgG and IgA, using both primary and secondary class-switching mechanisms. The HIV-1 IgA bNAbs have not been identified until now, mainly due to paucity of IgA responses to HIV-1, as compared with that of IgG ([@bib53]). Therefore, previous bNAb isolation efforts and NGS analyses of BCR repertoires have focused on IgG^+^ B cells and missed IgA^+^ B cells ([@bib15], [@bib86], [@bib85]). Here, we included the IgA transcripts in BCR repertoire analyses, and our positive findings are also a result of the fact that the two studied donors had mounted significant IgA bNAb responses to HIV-1. In contrast to previous studies where IgG bNAbs were artificially converted to IgA for functional analysis ([@bib16], [@bib75], [@bib82]), these IgA bNAbs were naturally produced in patients during HIV-1 chronic infection, thus making it feasible to assess naturally produced IgA bNAbs for protection and determine whether IgA bNAbs function similarly to or differently from their IgG counterparts at the mucosal portal of infection. This also provided a physiologically relevant example for class-switching from IgG to IgA, as a general immunological mechanism, in human antibodies with known specificity and function. This finding inspired subsequent and relevant questions such as whether the mechanism of IgG class-switching to IgA is common for HIV-1 bNAbs, and what factors determine which bNAb clones class-switch to both IgG and IgA. More importantly, epitope mapping and a cryo-EM structure revealed that these two bNAb lineages targeted two different epitopes, one at the V3 loop but independent of glycans and the other at the V2V5 corridor. Because previous antibodies targeting the V3 crown of HIV-1 gp120 can only neutralize tier 1 viruses and are weak against tier 2 viruses ([@bib2], [@bib40]), the V3 epitope defined by M4008_N1 and its clonal variants that conferred 42% (with IC~50~ \< 50 μg/mL) or 23% (with IC~50~ \< 1 μg/mL) of tier 2 virus neutralization is highly relevant for immunogen design targeting the V3 loop ([@bib96]), an immunodominant region of HIV-1 Env. Further structural analysis of M4008_N1 in complex with HIV-1 Env will help determine the specific antibody residues that contact V3 and confer effective tier 2 virus neutralization. Because the V3 crown epitope and the V2V5 corridor epitope reported here were distinct from those previously described, both added a site of vulnerability on the HIV-1 Env and thus were relevant to Env immunogen design. It is still unclear whether these specific sites are intrinsic factors or are coincident with the unusual class-switching to both IgG and IgA. With more such bNAb clones to be discovered and characterized, the intrinsic properties associated with bNAb clones that class-switch to both IgG and IgA will be unveiled.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Xueling Wu (<xw2702@cumc.columbia.edu>).

### Materials Availability {#sec4.2.2}

Expression plasmids encoding VSV~AD17~-mNG and bNAbs, including the representative bNAb lineage members, will be deposited to the NIH AIDS Reagent Program. The 293T-furin cell line with elevated human furin expression will be deposited to the NIH AIDS Reagent Program as well.

### Data and Code Availability {#sec4.2.3}

Sequences of M4008 and M1214 bNAbs and their NGS-derived heavy and light chains of variable region are available in GenBank under accession \# MT110156-MT110176. The NGS data used in this study have been deposited in the NCBI Sequence Read Archive (<https://www.ncbi.nlm.nih.gov/sra>) under accession SRP250531 for M4008 and SRP111345 for M1214. The crystal structure of M1214_N1 Fab has been deposited in the Protein Data Bank (PDB: [6VU2](pdb:6VU2){#intref0075}). The Cryo-EM reconstruction of M1214_N1 Fab in complex with CH505 SOSIP has been deposited in the Electron Microscopy Data Bank as EMD-21456 and the Protein Data Bank (PDB: [6VY2](pdb:6VY2){#intref0080}).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Cell Lines {#sec4.3.1}

Human embryonic kidney 293 cell line, of which the sex is female, is the parental cell for 293T and Expi293F cell lines. 293T was obtained from ATCC and maintained as adherent cells in complete DMEM medium at 37°C. 293T is highly transfectable and contains SV40 T-antigen. The full-length human furin gene was synthesized and cloned into a CSIB-based vector ([@bib31]), which was then used to transduce 293T cells; single cell clones were selected in 5 μg/mL blasticidin, and those with elevated human furin expression (293T-furin) were expanded and maintained as adherent cells in complete DMEM medium with 5 μg/mL blasticidin at 37°C. Expi293F was obtained from Thermo Fisher and adapted to suspension culture in Expi293 Expression Medium at 37°C. TZM-bl, of which the sex is female, was obtained from the NIH AIDS Reagent Program and maintained as adherent cells in complete DMEM medium at 37°C. TZM-bl is a HeLa cell line that expresses CD4 receptor and CXCR4 and CCR5 chemokine co-receptors; the cell line also expresses luciferase and β-galactosidase under the control of the HIV-1 promoter, hence is useful to assay in-vitro HIV-1 infection.

### Patient Samples {#sec4.3.2}

The two HIV-1^+^ plasma and PBMC samples were obtained from the Montreal HIV infection cohort ([@bib4], [@bib76]). The infection time for both donors was over 20 years, and the donors were not on antiretroviral therapy at the time of sampling. We worked with de-identified specimens that contained no information on the age or gender of the patients. All participant samples were collected under Institutional Review Board (IRB) approved protocols and with written informed consent obtained prior to enrollment.

Method Details {#sec4.4}
--------------

### Antibodies, Plasmids, and Proteins {#sec4.4.1}

The anti-CD4bs bNAbs, b12, HJ16, VRC01, VRC03, VRC-PG04 and N6, the anti-co-receptor-binding site (CoRbs) mAb 17b, the anti-V3 stem glycan bNAb PGT128, and the anti-gp120 glycan bNAb 2G12 were obtained through the NIH AIDS Reagent Program, as contributed by Drs. Dennis Burton, Carlos Barbas, Antonio Lanzavecchia, John Mascola, Mark Connors and James Robinson, by International AIDS Vaccine Initiative (IAVI), and by Division of AIDS, NIAID, NIH. The anti-CD4bs bNAb N49P7 was kindly provided by Dr. Mohammad Sajadi. The anti-V3 crown mAbs 447-52D, 2219, and 2424 were provided by Drs. Susan Zolla-Pazner and Miroslaw Gorny, and the anti-V3 crown mAb AD358_b7 has been described ([@bib29]). The 2-domain sCD4 (sCD4-183) was obtained through the NIH AIDS Reagent Program, from Pharmacia, Inc. ([@bib20]). The expression plasmids encoding the constant region of human IgG1 heavy chain, kappa chain, and lambda chain have been described ([@bib74]). The constant region sequences of human IgA1 and IgA2 heavy chains as well as the human J chain gene were synthesized and cloned into pcDNA3.1 (Invitrogen). Likewise, the membrane bound human IgG1 heavy chain sequences encoding VRC07 and PGT145 were synthesized and cloned into pcDNA3.1. The CD4-Ig expression plasmid was provided by Dr. Joseph Sodroski, and the CD4-Ig fusion protein was expressed by transient transfection of 293F cells and purified with Pierce recombinant protein A agarose (Thermo Fisher Scientific). The JR-FL gp120 was described ([@bib29]). The expression plasmids encoding Yu2 gp120 and Yu2 gp140 foldon were provided by Drs. Joseph Sodroski and Richard Wyatt, respectively, and the proteins were expressed by transient transfection of 293F cells and purified via His-tag with HisTalon gravity column (Clontech, Mountain View, CA). The CH505 SOSIP trimer was purchased from the Protein Production Facility at Duke Human Vaccine Institute.

### VSV~*AD17*~ Construct and Probe Preparation {#sec4.4.2}

As described ([@bib41]), the plasmids encoding full-length VSV genome (pVSV-FL) as well as individual VSV genes N, P, L, and G were purchased from Kerafast (Boston, MA). The plasmid encoding the HIV-1 strain AD17 was obtained from the NIH AIDS Reagent Program, as contributed by Drs. Beatrice Hahn and George Shaw. The chimeric Env was generated using overlap-extension PCR, in which the extracellular and transmembrane domains of AD17 Env were fused to the cytoplasmic tail of VSV-G. The chimeric Env DNA fragment was inserted into pVSV-FL precisely in place of the VSV-G to generate pVSV~AD17~. A plasmid bearing VSV cDNA encoding a monomeric NeonGreen-phosphoprotein P fusion protein (mNG-P) has been described ([@bib33], [@bib71]). Here, the VSV-G in pVSV-mNG-P was replaced with the chimeric Env DNA fragment to generate pVSV~AD17~-mNG-P. The VSV~AD17~ virus was rescued by infecting 293T cells with T7-expressing vaccinia (vTF7-3) at a MOI of 5, followed by transfection with pVSV~AD17~ (or pVSV~AD17~-mNG-P) and plasmids encoding VSV-N, P, L, and G under the control of a T7 promotor. Supernatant was harvested in 48 h, slowly filtered (0.22 μm) to remove vaccinia and plaque purified on GHOST.R5 cells. Plaque purified VSV~AD17~ was expanded in GHOST.R5 cells, filtered (0.22 μm), and stored in aliquots at −80°C. To prepare VSV~AD17~-PE, an aliquot of VSV~AD17~ was used to infect a T-75 flask of GHOST.R5 cells; at 24 h after infection, 20 mL of freshly collected VSV~AD17~ supernatant was filtered (0.22 μm) and pelleted by ultracentrifugation; the viral pellet was then labeled with PE (Abcam, Cambridge, MA). To prepare VSV~AD17~-mNG, an aliquot of VSV~AD17~-mNG was used to infect a T-75 flask of pVSV-G transfected GHOST.R5 cells; at 24 h after infection, the VSV~AD17~-mNG (decorated with VSV-G) supernatant was filtered (0.22 μm) and used to infect (single-round infection) a T-75 flask of pre-seeded 293T-furin cells; at 24 h after infection, the 293T-furin cells were inspected under green fluorescent microscope for \> 90% confluence and \> 90% green fluorescence; 20 mL of freshly collected VSV~AD17~-mNG supernatant was filtered (0.22 μm) and directly used to stain B cells.

### Fluorescence Activated Cell Sorting, Single B cell RT-PCR, Antibody Expression and Purification {#sec4.4.3}

Patient or blood donor PBMC samples were pre-sorted for B cells by FACS. Briefly, donor PBMCs were stained with anti-human CD3-PE-CF594 (BD Biosciences, San Jose, CA), CD19-PE-Cy7 (BioLegend, San Diego, CA), and CD20-APC-Cy7 (BioLegend), and the CD3-CD19+ B cells were bulk sorted. In addition, live/dead yellow stain (Invitrogen) was used to exclude dead cells. The bulk sorted B cells were then re-stained with anti-human CD3-PE-CF594, CD19-PE-Cy7, CD20-APC-Cy7, with additional staining of IgM-V450 (BD Biosciences), IgG-FITC (BD Biosciences) and VSV~AD17~-PE, or IgM-V450 and CD27-PerCP-Cy5.5 (BD Biosciences) with VSV~AD17~-mNG. Fluorescence compensation was performed with anti-mouse Ig κ beads (BD Biosciences) stained with each antibody in a separate tube. After washing, cells were analyzed and sorted using a multi-laser MoFlo sorter (Beckman Coulter, Jersey City, NJ) contained with Biosafety Level 3 standards; single cells were sorted into 96-well PCR plates containing 20 μL lysis buffer, consisting of 5 μL 5 × first-strand buffer (Invitrogen), 1.25 μL 0.1 M DTT, 0.5 μL RNaseOut, and 0.0625 μL Igepal (Sigma, St. Louis, MO). The total content of cells passing through the sorter was analyzed with FlowJo (TreeStar, Cupertino, CA). The PCR plates with sorted cells were frozen on dry ice and stored at −80°C.

From each sorted cell, the variable regions of antibody heavy and light chains were amplified by RT-PCR as described ([@bib29], [@bib74]). Briefly, frozen plates with single B cell RNA were thawed at room temperature, and RT was carried out by adding into each well 3 μL random hexamers at 150 ng/μL (Gene Link, Hawthorne, NY), 2 μL dNTP (each at 10 mM), and 1 μL SuperScript III (Invitrogen), followed by 42°C for 10 min, 25°C for 10 min, 50°C for 60 min and 94°C for 5 min. After RT, 25 μL water was added to each well to dilute cDNA. The heavy and light chain variable regions were amplified independently by nested PCR in 50 μL, using 5 μL cDNA as template, HotStarTaq Plus DNA polymerase (QIAGEN) and primers or primer mixes as described ([@bib62], [@bib74]). Cycler parameters were 94°C for 5 min, 50 cycles of 94°C for 30 s, 52-55°C for 30 s, and 72°C for 1 min, followed by 72°C for 10 min. The PCR amplicons were sequenced and analyzed using IMGT/V-QUEST (<http://www.imgt.org/>). Selected PCR sequences that gave productive heavy or light chain rearrangements were reamplified with custom primers containing unique restriction digest sites and cloned into the corresponding human IgG1, IgA1, or IgA2 heavy and light chain expression vectors. Full-length human IgG1, IgA1, or IgA2 proteins were expressed by co-transfecting 293F cells (Invitrogen) with equal amounts of paired heavy and light chain plasmids (along with the human J chain plasmid for dimeric IgA) and purified using Pierce recombinant protein A agarose (Thermo Fisher Scientific) for IgG1 or CaptureSelect IgA Affinity Matrix (Life Technology) for IgA. For each batch of purified dimeric IgA, an analytic size-exclusion chromatography (SEC) was performed to assure \> 90% purity. To purify IgA from donor plasma, 1 mL of donor plasma was first passed through a Pierce Protein G UltraLink Column (Thermo Fisher Scientific) to bind IgG, and the IgA in the flow through was then purified using peptide M agarose (InvivoGen).

### Enzyme-linked Immunosorbent Assay (ELISA) {#sec4.4.4}

As previously described ([@bib29], [@bib84]), ELISA plates were coated with HIV-1 gp120 at 2 μg/mL or gp140 at 5 μg/mL in PBS at 4°C overnight. For liganded gp140, sCD4, VRC01 Fab, or M1214_N1 Fab was incubated with the same amount of unliganded gp140 in 50 μL of PBS at 37°C for 30 min before used to coat plates at a final concentration of 1 μg/mL in PBS. After blocking with 1% BSA in PBS at 37°C for 1 h, serially diluted antibodies were incubated at 37°C for 1 h. Horseradish peroxidase (HRP)-conjugated goat anti-human IgG Fc antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) was added at 37°C for 1 h. All volumes were 100 μL/well except 200 μL/well for blocking. Plates were washed between each step with 0.1% Tween 20 in PBS, developed with 3,3′,5,5′-tetramethylbenzidine (TMB) (Kirkegaard & Perry Laboratories) and read at 450 nm. For competitive ELISA, serially diluted competitor antibodies or CD4-Ig were added in 50 μL of blocking buffer, followed by adding 50 μL of biotin-labeled antibodies or CD4-Ig at one pre-determined concentration. After incubation at 37°C for 1 h, 250 ng/mL of streptavidin-HRP (Sigma) was added at room temperature for 30 min. Plates were then developed with TMB and read at 450 nm.

### HIV-1 Neutralization Assay {#sec4.4.5}

Antibody neutralization was assessed based on the single-round infection assay of TZM-bl cells with HIV-1 Env pseudoviruses as described ([@bib29], [@bib68], [@bib67]). Mutant Envs were generated by TagMaster Site-Directed Mutagenesis Kit (GM Biosciences, Frederick, MD) and tested along with the corresponding wild-type virus. Briefly, 50 or 100 μL of antibody-virus mixture was incubated at 37°C for 30 min in duplicate wells before the addition of TZM-bl cells. To keep assay conditions constant, sham medium was used in place of antibody or plasma in control wells. Infection levels were determined in 2 days with Bright-Glo luciferase assay system (Promega, Madison, WI). Neutralization curves were fitted to a 5-parameter nonlinear regression analysis through Prism 6.0 (GraphPad Software, La Jolla, CA) and the data were plotted as means with SEM (standard error of mean). The antibody concentration or plasma reciprocal dilution required to inhibit infection by 50% was reported as IC~50~ or ID~50~. Neutralization sensitivity was also color-coded for each tested Env in a dendrogram depicting the gp160 protein sequence distance. Briefly, the HIV-1 gp160 protein sequences of 120 isolates used in the neutralization assay were aligned using ClustalW in BioEdit (<https://bioedit.software.informer.com/>). The aligned protein sequences were submitted to Protdist and Neighbor phylogenetic tree in BioEdit; the tree was displayed with Dendroscope (<http://dendroscope.org>) and then color-coded according to the neutralization sensitivity.

### 5′ RACE and Next-Generation Sequencing (NGS) of B Cell Receptor (BCR) Repertoires {#sec4.4.6}

As described ([@bib79]), cellular mRNA was extracted from the donor PBMCs using the Oligotex Direct mRNA Mini Kit (QIAGEN). For 5′ RACE cDNA synthesis, each 10 μL mRNA was mixed with 1 μL Oligo dT~12-18~ at 12 μM (Life Technologies) at 70°C for 1 min and then −20°C for 1 min, followed by addition of 1 μL SMARTer Oligo at 12 μM (Clontech), 4 μL 5x first-strand buffer, 1 μL DTT at 20 mM, 1 μL dNTP at 10 mM each, 1 μL RNaseOUT, and 1-3 μL SuperScript II (Life Technologies). The mixtures were incubated at 42°C for 2 h and then passed through a PCR cleanup spin column (Machery-Nagel). The KAPA HiFi qPCR kit (KAPA Biosystems) with a universal 5′ IIA primer (Clontech) was used to amplify the variable region of μ, γ, α, κ, and λ chains from a single cDNA sample, in combination with a mixture of 3′ primers specific for μ, γ, α, κ, and λ chains. Primers each contained a unique 8 bp Illumina barcode for demultiplexing after Miseq sequencing. The PCR cycling conditions were 98°C for 45 s, 16-22 cycles of 98°C for 15 s, 65°C for 30 s, and 72°C for 45 s, followed by 72°C for 3 min. The PCR products were loaded on a 2% E-gel (Life Technologies) for visualization and extraction, with a final buffer exchange using the PCR Micro Kit (Life Technologies). The eluted PCR DNA was used for Illumina MiSeq library preparation and 2 × 300 bp paired-end indexed sequencing at the New York Genome Center with 2--3 PCR samples multiplexed per run.

### Analysis of NGS Data {#sec4.4.7}

The 2 × 300 bp MiSeq raw reads were assembled to single transcripts using USEARCH ([@bib17]), which calculated the number of low-quality calls based on Q scores in each transcript and excluded the transcripts with more than 20 potential miscalls. Our bioinformatics pipeline, SONAR, was then used to annotate antibody transcripts ([@bib66]). Briefly, transcripts shorter than 300 nucleotides were removed. BLAST (<http://www.ncbi.nlm.nih.gov/blast/>) with optimized parameters was used to assign germline V, J, and C genes for each transcript with germline genes obtained from the IMGT database (<http://www.imgt.org/>). CDR3 was identified from boundaries of V and J genes and the conserved 2nd Cysteine in the V region and WGXG (heavy chain) or FGXG (light chain) amino acid motifs in the J region (X represents any of the 20 amino acids). The open-reading frame was then determined and the sequences other than the V(D)J region were removed. Transcripts containing frameshift or stop codons were excluded. Transcripts of heavy chains without a CH1 gene annotation were also excluded.

### Antibody Lineage Analysis {#sec4.4.8}

For each antibody lineage of interest, the MiSeq transcripts sharing identical germline V and J genes were identified from the IgM, IgG, and IgA repertoires. Identity-divergence plot (2D plot) was employed to identify the members of each antibody lineage. Briefly, the nucleotide sequence of each transcript was aligned to the reference antibody and assigned germline V gene using MUSCLE (<http://www.drive5.com/muscle>), and the identity to reference antibody and the somatic hypermutation level was calculated. On the 2D plots, we selected transcripts from islands showing high identity to reference antibodies. We then analyzed the junctions (VDJ or VJ) of transcripts and removed those having junctions different from the reference antibodies. To eliminate possible PCR crossover, we removed transcripts that had a similar CDR3 sequence but did not share any somatic hypermutation in the V gene with the reference antibodies. To further select representative transcript of each lineage, we used USEARCH to cluster transcripts with 0.99 identity as described ([@bib15], [@bib69], [@bib86]). Transcripts were ranked based on sequencing depth or number of replicates, and the representative transcripts with highest coverage were selected for gene synthesis and expression. The phylogenetic analysis of the heavy chains of selected bNAb lineages was performed with the lineage members aligned using ClustalO ([@bib70]), and maximum likelihood trees were constructed using MEGA7 ([@bib72]) with GTR+G substitution model.

### M1214_N1 Fab Crystal Structure Determination {#sec4.4.9}

The Fab fragment of M1214_N1 was produced by papain digestion as described ([@bib5], [@bib11]). Preliminary crystallization condition was obtained and optimized by robotic screening using the hanging-drop vapor diffusion method. Good diffracting crystals of M1214_N1 Fab at 10 mg/mL were grown in a solution of 28% PEG8000, 1.6M calcium acetate and 20% glycerol. X-ray diffraction data were collected at beam line AMX, National Synchrotron Light Source II (NSLS II), Brookhaven National Laboratory. All datasets were processed using the XDS software package ([@bib30]), and structures were determined by molecular replacement software Phaser ([@bib51]). Structural model building was carried out using COOT ([@bib18]), and refinement was calculated by Phenix ([@bib1]). CαRMSDs were calculated by SuperPose ([@bib49]).

### Cryo-EM sample Preparation and Data Acquisition {#sec4.4.10}

The CH505 SOSIP.664 trimer ([@bib61], [@bib92]) was incubated with a 6-fold molar excess of Fab MT1214_N1 overnight at 4°C. Excess Fab was removed and the complex was concentrated to 0.2 mg/mL using a 100-kDa cutoff concentrator (Amicon Ultra, Millipore). A 4 μL aliquot of the sample was applied onto a glow-discharged C-Flat 1.2/1.3 grid (Electron Microscopy Sciences, Protochips, Inc.), blotted and then plunged into liquid ethane using FEI Vitrobot Mark IV to capture complexes in vitreous ice. Micrographs were collected on a Talos Arctica operating at 200 KeV coupled with a Gatan K2 direct electron detector using the SerialEM interface ([@bib50]). Each exposure image was collected in super-resolution mode at 36,000x magnification resulting in a pixel size of 0.58 Å/pixel, using a dose rate of ∼8 e^-^/pix/sec, and 250 ms exposure per frame. A total of 2,350 micrographs were collected at a random nominal defocus range between −1.5 and −3.5 μm.

Movie micrograph frames were aligned using MotionCor2 ([@bib89]) and binned by 2 to a pixel size of 1.16 Å. The contrast-transfer-function (CTF) estimation was performed for each aligned micrograph using CTFFIND4 ([@bib59]) without dose-weighting. All single particle processing including particle picking, 2D and 3D classification was performed using RELION-3.0 ([@bib63]), and 3D refinement and map sharpening were carried out by cryoSPARC 2.14 ([@bib58]). Briefly, around 2,000 particles were manually picked and sorted to generate an initial model as a template for particle auto-picking. After manual inspection, a total of 209,276 particles from 783 images were extracted and sorted by two rounds of reference-free 2D class averaging along with subset selection. The sorted particles were further sorted by 3D heterogeneous refinement using an Ab-initio model and C1 symmetry. The 94,839 particles belonging to the best 3D classes were used for an unbinned refinement and reconstruction. The overall resolution of the final map was determined to 4.86 Å, based on the gold-standard Fourier shell curve using a correlation cut-off of 0.143 ([Figures 5](#fig5){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}).

Model building for the CH505 SOSIP trimer in complex with Fab M1214_N1 was initiated by searching a homology model with SWISS-MODEL ([@bib3]) using CH505 SOSIP (PDB: [6UDA](pdb:6UDA){#intref0115}) as a template. Separate gp120 and gp41 models were generated, fitted into the cryo-EM map, and combined as a trimeric complex with three copies of crystal structure of Fab MT1214_N1 (PDB: [6VU2](pdb:6VU2){#intref0120}) using UCSF Chimera ([@bib57]). Initial refinement was done using Phenix ([@bib1]). Glycans were built into the map using the carbohydrate module in COOT ([@bib18]) as N-linked NAG-NAG-BMA and subsequently extended or trimmed to match EM map densities. Final refinements were performed iteratively using Phenix ([@bib1]) real-space refinement with secondary structure restraint along with manual building using COOT ([@bib18]). Model validation was done using MolProbity ([@bib13]). Surface contacts were calculated and colored using PyMOL ([pymol.org](http://pymol.org){#intref0125}).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

GraphPad Prism 6.0 was used to plot the ELISA data using sigmoidal dose-response with variable slope for curve fitting and the neutralization data using 5-parameter nonlinear regression for curve fitting. No statistical analysis for group comparisons was needed in this study.
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